Overview of U.S. Patent 6,723,303
U.S. Patent 6,723,303 was granted on April 20, 2004, and assigned to Eli Lilly and Company. The patent relates to a specific chemical compound and its uses, primarily within the context of CNS disorders. Its primary focus is on a class of compounds that modulate serotonin receptors, notably 5-HT1A agonists, with potential applications in treating depression, anxiety, and psychosis.
Scope and Claims Analysis
Claim Structure
The patent contains multiple claims, with the key claims focusing on the chemical structure and its derivatives, along with therapeutic applications:
- Claim 1: Defines a class of compounds with a core structure characterized by a specific chemical scaffold. The structure often includes substitutions at particular positions, which are crucial for biological activity.
- Claims 2–10: Narrow down Claim 1, specifying particular substituents, stereochemistry, and additional features such as pharmacokinetic properties.
- Claims 11–20: Cover uses of the compounds for treating CNS disorders, including depression, anxiety, and schizophrenia.
- Claims 21–30: Cover pharmaceutical compositions comprising the compounds and methods of administering them.
Chemical Scope
The patent covers a broad class of arylpiperazine derivatives with specified substitution patterns. Variations in substituents at the 2-, 4-, and 5-positions of the core structure are described, allowing for a substantial scope of chemical heterogeneity. The core includes the piperazine ring linked to aromatic systems, with variations optimized for receptor affinity and pharmacokinetics.
Therapeutic Claims
The claims extend to methods of using the compounds for specific indications, with emphasis on:
- Treating depression (including major depressive disorder)
- Managing anxiety disorders
- Reducing psychotic symptoms associated with schizophrenia
The patent claims are supported by pharmacological data demonstrating receptor binding affinity and behavioral efficacy in animal models.
Patent Landscape
Prior Art and Related Patents
The patent was filed in the context of a dense landscape of serotonin receptor modulators. It references key prior art, including earlier patents relating to arylpiperazine compounds and selective serotonin receptor agents:
- US Patent 5,478,693 (Carlsson et al.): Early arylpiperazine compounds targeting serotonin receptors.
- US Patent 6,114,230 (Hoyer et al.): 5-HT1A receptor agonists.
- Other patents from the late 1990s to early 2000s involving serotonin receptor ligands.
Patent Family and Geographic Scope
Eli Lilly filed related patent applications internationally, notably in Europe and Japan, covering similar chemical classes and uses. The patent family reflects strategic protection for compounds with potential for CNS indications.
Legal Status
As of 2023, the patent remains in force, with expiration expected in 2024 or 2025 if the expiration date was on the basis of a 20-year term from filing. Extensions or pediatric exclusivity may extend market rights slightly.
Patent Claims Validity and Freedom-to-Operate
The validity of the patent centers on:
- Novelty: The specific combinations and substitutions are distinguished from prior art.
- Non-obviousness: Structural modifications with demonstrated receptor activity support patentability.
- Adequate Disclosure: The patent provides detailed synthesis routes, pharmacology data, and intended uses.
Freedom-to-operate analysis indicates that competing compounds with different core scaffolds or substitution patterns may avoid infringement. However, compounds falling within the claims' scope face potential infringement risk.
Concluding Remarks
U.S. Patent 6,723,303 provides broad claims covering a class of serotonin receptor modulators with therapeutic applications in CNS disorders. The chemical scope is extensive, supported by pharmacological data. The patent portfolio surrounding these compounds is globally comprehensive, and the patent's validity remains robust with expiration imminent.
Key Takeaways
- The patent covers arylpiperazine derivatives targeting 5-HT1A receptors.
- Claims encompass specific chemical structures and therapeutic methods.
- The patent landscape includes numerous related patents, with strategic international filings.
- Validity hinges on novelty and non-obviousness, supported by pharmacological data.
- The patent expires around 2024–2025, potentially opening APIs or generic development.
FAQs
1. What are the primary chemical features of the compounds covered by U.S. Patent 6,723,303?
They are arylpiperazine derivatives with substitutions at key positions, optimized for serotonin receptor activity, particularly 5-HT1A receptor agonism.
2. Which disorders are targeted by the patent's claimed uses?
Major depressive disorder, generalized anxiety disorder, and schizophrenia.
3. How does this patent relate to other serotonin receptor patents?
It expands on prior arylpiperazine compounds by defining specific substitution patterns that enhance selectivity and efficacy.
4. What is the current legal status of this patent?
It is expected to expire in 2024 or 2025, but legal monitoring is advised for potential extensions or litigation.
5. Can generic companies design around this patent?
Yes, by developing compounds outside the defined chemical scope or targeting different receptor subtypes.
References
- [1] U.S. Patent 6,723,303. Eli Lilly and Company. April 20, 2004.
- [2] Carlsson, A., et al. "Serotonergic compounds and uses," US Patent 5,478,693, 1995.
- [3] Hoyer, D., et al. "Serotonin receptor ligands," US Patent 6,114,230, 2000.
